Thermo Fisher Scientific Stock Skyrockets: Here’s Why It’s Dominating the Market Today

Thermo Fisher Scientific just left the broader market in the dust—and Wall Street is scrambling to catch up.

Analysts point to a perfect storm of catalysts: blockbuster earnings that shattered expectations, a groundbreaking new product launch that's set to redefine the diagnostics space, and a major contract win that locks in revenue for quarters to come. The stock isn't just climbing; it's staging a full-scale breakout while traditional value plays flatline.

Institutional money is flooding in, betting big on the long-term growth of life sciences tools—because let's be honest, while bankers debate P/E ratios, scientists are busy curing diseases and printing cash.

This isn't a fluke. It's a sector-wide signal that innovation still trumps financial engineering—no matter what the crypto-skeptics say about 'real world assets.'

Buy, says a new bull

Happily for investors, that pundit is bullish on Thermo Fisher's future. William Blair analyst Matt Larew ranked the healthcare device and services company's stock as an outperform (buy, in other words); it was unclear as of this writing if he set a price target.

Image source: Getty Images.

According to reports, Larew believes Thermo Fisher has numerous competitive advantages, and is leveraging them well. He wrote in his inaugural analyst note that the company offers best-in-class services, and with its range of products and services can act as something of a one-stop shop for customers.

On a slightly negative note, Larew pointed out that the company's Core biopharma client base is currently experiencing a degree of softness. However, he feels that with its extensive lineup of quality offerings, Thermo Fisher is well positioned to take advantage of that segment when it recovers.

Oversold and undervalued

Thermo Fisher's shares have been in something of a funk; in contrast to numerous other healthcare titles, they are down in price since the start of the year.

Its recent fundamentals have been better than expected -- second-quarter revenue rose by almost 3% (to almost $10.9 billion), and non-GAAP (generally accepted accounting principles) adjusted EPS was at $5.36. Although both figures beat the consensus analyst estimates, they weren't crushing beats, and that top-line growth wasn't remarkable enough to MOVE the stock.